News | Stents Drug Eluting | January 08, 2016

Stentys Completes Enrollment of MiStent Randomized Trial Against Xience

DESSOLVE III clinical trial enrolled 1,400 “all-comers” patients, with primary endpoint of non-inferiority comparison of target lesion failure

January 8, 2016 — In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical trial will compare the MiStent SES sirolimus eluting absorbable polymer coronary stent system to Abbott’s Xience stent.

The MiStent SES is a balloon-expandable stent designed to improve long-term clinical outcome of patients treated with conventional “workhorse” stents. The device features Crystalline Sirolimus technology, where thousands of microscopic drug crystals slowly dissolve in the surrounding tissue after absorption of the polymer carrier. This allows for a gradual, linear and much longer elution of sirolimus than with other competitive stents, hence reducing vessel over-scarring.

With 2 percent re-intervention rate (target lesion revascularization) at three-year follow-up in previous clinical trials, MiStent SES was shown to be superior to Xience in a retrospective propensity analysis presented by Alexandra Lansky, M.D., New Haven, Conn., during the last EuroPCR conference in Paris.

DESSOLVE III is a prospective, balanced, randomized, controlled, single-blind, multi-center study comparing clinical outcomes between MiStent SES and Xience in a “real world, all-comers” patient population of 1,400 patients in 20 hospitals in Europe. Patients in the trial suffered from symptomatic coronary artery disease, including those with chronic stable angina, silent ischemia or acute coronary syndrome, and qualified for percutaneous coronary interventions. The primary endpoint is a non-inferiority comparison of target lesion failure (TLF) of the MiStent SES group versus the Xience group at 12 months post-procedure.

MiStent SES has already received CE Marking. Stentys is MiStent exclusive distributor worldwide, except in the United States, Canada, China, South Korea and Japan, and is currently conducting a controlled launch in select countries in Europe, Middle East and Asia.

For more information: www.stentys.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init